Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

被引：0
|
作者：
Carole Dembek
Leigh Ann White
Jayson Quach
Andrea Szkurhan
Nazia Rashid
M. R. Blasco
机构：
[1] Avalere Health,
[2] Biogen Idec,undefined
[3] Dymaxium,undefined
[4] Hospital Universitario Puerta de Hierro,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Multiple sclerosis; Cost-effectiveness; Disease-modifying therapies; Interferon-beta; I1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 362
页数：9
相关论文
共 50 条
  • [1] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Dembek, Carole
    White, Leigh Ann
    Quach, Jayson
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04): : 353 - 362
  • [2] Cost-Effectiveness of Injectable Disease-Modifying Therapies in the Treatment of Multiple Sclerosis
    Quach, Jayson
    Dembek, Carole
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    NEUROLOGY, 2011, 76 (09) : A474 - A474
  • [3] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [4] Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
    Ali Manouchehrinia
    Cris S. Constantinescu
    Current Neurology and Neuroscience Reports, 2012, 12 : 592 - 600
  • [5] Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
    Manouchehrinia, Ali
    Constantinescu, Cris S.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (05) : 592 - 600
  • [6] COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE
    Petropoulos, A.
    Cooney, P.
    Patidar, M.
    Gudala, K.
    Tiwari, S.
    Brennan, R.
    Kapsogeorgiou, K.
    Cheilas, G.
    Banhazi, J.
    VALUE IN HEALTH, 2022, 25 (12) : S80 - S81
  • [7] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [8] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A VS. FIRST LINE INJECTABLE DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Ruiz, L.
    Toro-Diaz, H.
    Cele, C.
    Hernandez, L.
    Harrington, A.
    VALUE IN HEALTH, 2017, 20 (09) : A723 - A723
  • [9] Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis
    Rezaee, Mehdi
    Ravangard, Ramin
    Mojtabaeian, Seyyed Morteza
    Jafari, Abdosaleh
    BMC HEALTH SERVICES RESEARCH, 2024, 24 (01)
  • [10] Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature
    Yamamoto, David
    Campbell, Jonathan D.
    AUTOIMMUNE DISEASES, 2012, 2012
12345